VectorBuilder and Lir Advance AI-Driven AAV Capsids
Chicago, Illinois, August 18, 2026 VectorBuilder and Lir Therapeutics have announced a strategic collaboration to advance adeno-associated virus (AAV)...
genetic medicine
Advertisement
PTC Therapeutics to Acquire ST-920 Fabry Gene Therapy Program
Warren, New Jersey, August 12, 2026 PTC Therapeutics announced that it was selected as the winning bidder to acquire...
Calidi Biotherapeutics Highlights CLD-401 Cancer Therapy Data
SAN DIEGO, July 27, 2026 Calidi Biotherapeutics presented new preclinical data from its CLD-401 program and its in situ...
Waters Strengthens Clinical Diagnostics with Xevo XR Innovation
MILFORD, Mass., July 27, 2026 Waters Corporation has introduced the Xevo™ TQ Absolute XR IVD Mass Spectrometer, expanding its...
BioMarin Partners n-Lorem on First ReNU Syndrome Therapy
SAN RAFAEL, Calif. & SAN DIEGO, July 27, 2026 BioMarin Pharmaceutical Inc. and the n-Lorem Foundation have announced a...
Advertisements
Primrose Bio Earns $2M NIH Award for RNA Therapeutics
SAN DIEGO, Calif., July 15, 2026 Primrose Bio, Inc. has secured a $2 million Direct-to-Phase II Small Business Innovation...
Apertura Gene Therapy Advances NPC1 Gene Therapy Research
NEW YORK | July 9, 2026 Apertura Gene Therapy, a biotechnology company developing next-generation adeno-associated virus (AAV) capsids for...
ARTAN Bio Secures $1M Seed Round for tRNA Platform
ST. PETERSBURG, Fla., July 1, 2026 ARTAN Bio has announced the successful completion of a $1 million seed financing...
REGENXBIO Doses First Patient in NAAVIGATE Gene Trial
ROCKVILLE, Md., June 29, 2026 REGENXBIO Inc. has reached a major milestone in the advancement of gene therapy for...
Nippon Shinyaku, Elixirgen Sign EXG-7001 DMD Option Deal
KYOTO, Japan, June 26, 2026 Nippon Shinyaku Co., Ltd. announced it has entered into an option agreement with Elixirgen...
Advertisement
